Supernus Pharma to acquire Adamas Pharma and with it Gocovri ,which is FDA approved for Parkinson's disease
Supernus Pharmaceuticals Inc, and Adamas Pharmaceuticals, Inc., announced a definitive agreement for Supernus to acquire Adamas through a tender offer for $8.10 per share in cash (or an aggregate of approximately $400 million), payable at closing plus two non-tradable contingent value rights (CVR) collectively worth up to $1.00 per share in cash (or an aggregate of approximately $50 million), for a total consideration of $9.10 per share in cash (or an aggregate of approximately $450 million).